Chorea

Heterogeneous Movement Disorders in Patients With C9orf72 Hexanucleotide Expansions

Jessica Nye, PhD

April 12, 2021

In this retrospective review, study researchers sought to assess the presentation of movement disorders in carriers of C9orf72 hexanucleotide repeat expansions.

Movement Disorders

Evaluating the Effects of Treatment Conversion for Huntington’s Chorea

Haymarket Media

July 27, 2017

Overnight treatment conversion from tetrabenazine to deutetrabenazine in patients with HD was found to be safe.

Movement Disorders

Tardive Dyskinesia Treatment Approved by FDA

Alicia Ciccone

April 12, 2017

Valbenazine is the first drug approved for the treatment of tardive dyskinesia, an adverse effect associated with the use of some antipsychotic medications.